Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 559-577 , September 2008

Cellular immunotherapy for multiple myeloma

  • Jacalyn Rosenblatt, MD (Doctor)
    • ,
  • David Avigan, MD (Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Kirstein RM 135, 330 Brookline Ave, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Tel.: +1 617 667 9920; Fax: +1 617 667 9922.

References 

  1. Bataille R, Harousseau JL. Multiple myeloma. The New England Journal of Medicine. 1997;336:1657–1664
  2. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematology/Oncology Clinics of North America. 1999;13:1295–1314xi
  3. Greipp PR. Prognosis in myeloma. Mayo Clinic Proceedings. 1994;69:895–902
  4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854
  5. Dewald GW, Kyle RA, Hicks GA, et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66:380–390
  6. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005;23:3412–3420
  7. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. The New England Journal of Medicine. 1994;330:484–489
  8. Jagannath S, Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematology/Oncology Clinics of North America. 1992;6:437–449
  9. Harousseau JL, Milpied N, Jouet JP, et al. Intensive therapy for high grade multiple myeloma (MM). Bone Marrow Transplantation. 1991;7(Suppl. 2):28
  10. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine. 1996;335:91–97
  11. Kyle RA, Rajkumar SV. Multiple myeloma. The New England Journal of Medicine. 2004;351:1860–1873
  12. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine. 2005;352:2487–2498
  13. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20–32
  14. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine. 1981;304:1529–1533
  15. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  16. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Journal of Clinical Oncology. 1995;13:1312–1322
  17. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology. 2001;113:209–216
  18. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. The New England Journal of Medicine. 1991;325:1267–1273
  19. Crawley C, Iacobelli S, Bjorkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588–3594
  20. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787–2793
  21. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology. 1999;17:208–215
  22. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of Clinical Oncology. 2000;18:2273–2281
  23. Harrison SJ, Cook G. Immunotherapy in multiple myeloma – possibility or probability?. British Journal of Haematology. 2005;130:344–362
  24. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–1198
  25. Zeiser R, Bertz H, Spyridonidis A, et al. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplantation. 2004;34:923–928
  26. Verdonck LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases. Lancet. 1996;347:800–801
  27. Bertz H, Burger JA, Kunzmann R, et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia. 1997;11:281–283
  28. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology. 2000;18:3031–3037
  29. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplantation. 2006;37:1135–1141
  30. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711–4718
  31. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98:934–939
  32. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100:3919–3924
  33. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood. 2002;100:3128–3134
  34. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454
  35. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–3480
  36. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. The New England Journal of Medicine. 2007;356:1110–1120
  37. Orsini E, Alyea EP, Schlossman R, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplantation. 2000;25:623–632
  38. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655–2661
  39. Takahashi T, Makiguchi Y, Hinoda Y, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. Journal of Immunology. 1994;153:2102–2109
  40. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Research. 2001;61:6846–6850
  41. Lim SH, Wang Z, Chiriva-Internati M, et al. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood. 2001;97:1508–1510
  42. Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leukemia & Lymphoma. 2006;47:2037–2048
  43. Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007;109:1103–1112
  44. Batchu RB, Moreno AM, Szmania SM, et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Research. 2005;65:10041–10049
  45. Hundemer M, Schmidt S, Condomines M, et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Experimental Hematology. 2006;34:486–496
  46. Chiriva-Internati M, Ferraro R, Prabhakar M, et al. The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. Journal of Translational Medicine. 2008;6:15
  47. Beckhove P, Schutz F, Diel IJ, et al. Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. International Journal of Cancer. 2003;105:444–453
  48. Yi Q, Osterborg A, Bergenbrant S, et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood. 1995;86:3043–3049
  49. van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939–3944
  50. Goodyear O, Piper K, Khan N, et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood. 2005;106:4217–4224
  51. Maxwell CA, Rasmussen E, Zhan F, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004;104:1151–1158
  52. Crainie M, Belch AR, Mant MJ, et al. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood. 1999;93:1684–1696
  53. Chen J, Schmitt A, Bunjes D, et al. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. International Journal of Oncology. 2007;30:1119–1127
  54. Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111:1357–1365
  55. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997;90:1217–1225
  56. Sugiyama H. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leukemia & Lymphoma. 1998;30:55–61
  57. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:13885–13890
  58. Tsuboi A, Oka Y, Nakajima H, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal of Hematology. 2007;86:414–417
  59. Lynch RG, Graff RJ, Sirisinha S, et al. Myeloma proteins as tumor-specific transplantation antigens. Proceedings of the National Academy of Sciences of the United States of America. 1972;69:1540–1544
  60. Houet L, Veelken H. Active immunotherapy of multiple myeloma. European Journal of Cancer. 2006;42:1653–1660
  61. Moshitzky S, Kukulansky T, Haimovich J, et al. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunology and Cell Biology. 2008;86:261–267
  62. Lauritzsen GF, Weiss S, Dembic Z, et al. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:5700–5704
  63. Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leukemia & Lymphoma. 2003;44:2031–2038
  64. Yi Q, Eriksson I, He W, et al. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. British Journal of Haematology. 1997;96:338–345
  65. Dabadghao S, Bergenbrant S, Anton D, et al. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British Journal of Haematology. 1998;100:647–654
  66. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood. 2001;97:1750–1755
  67. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. European Journal of Immunology. 1996;26:2671–2679
  68. Bogen B, Ruffini PA, Corthay A, et al. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica. 2006;91:941–948
  69. Bergenbrant S, Yi Q, Osterborg A, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. British Journal of Haematology. 1996;92:840–846
  70. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998;91:2459–2466
  71. Rasmussen T, Hansson L, Osterborg A, et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood. 2003;101:4607–4610
  72. Coscia M, Mariani S, Battaglio S, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004;18:139–145
  73. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016–1020
  74. Li Y, Bendandi M, Deng Y, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000;96:2828–2833
  75. Neelapu SS, Munshi NC, Jagannath S, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplantation. 2005;36:315–323
  76. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Reviews. 1999;13:51–64
  77. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102:1435–1442
  78. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clinical Cancer Research. 1998;4:957–962
  79. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer. 1999;83:215–222
  80. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. British Journal of Haematology. 1999;107:648–655
  81. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology. 2000;108:805–816
  82. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood. 1999;93:2411–2419
  83. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology Blood Marrow Transplantation. 2000;6:621–627
  84. Reichardt VL, Milazzo C, Brugger W, et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica. 2003;88:1139–1149
  85. Bendandi M, Rodriguez-Calvillo M, Inoges S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia & Lymphoma. 2006;47:29–37
  86. Lee JJ, Choi BH, Kang HK, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leukemia & Lymphoma. 2007;48:2022–2031
  87. Vasir B, Borges V, Wu Z, et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. British Journal of Haematology. 2005;129:687–700
  88. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine. 1997;3:558–561
  89. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:6279–6283
  90. Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002;99:2512–2517
  91. Hao S, Bi X, Xu S, et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Experimental Oncology. 2004;26:300–306
  92. Walewska R, Teobald I, Dunnion D, et al. Preclinical development of hybrid cell vaccines for multiple myeloma. European Journal of Haematology. 2007;78:11–20
  93. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+ CD25high regulatory cells in human peripheral blood. Journal of Immunology. 2001;167:1245–1253
  94. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. The Journal of Experimental Medicine. 2001;193:1303–1310
  95. Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. The Journal of Experimental Medicine. 2001;193:1285–1294
  96. Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4+ CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood. 2006;107:3940–3949
  97. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107:301–304
  98. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Research. 1999;59:3128–3133
  99. Javia LR, Rosenberg SA. CD4+ CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. Journal of Immunotherapy. 2003;26:85–93
  100. Prasad SJ, Farrand KJ, Matthews SA, et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+ CD25+ regulatory T cells. Journal of Immunology. 2005;174:90–98
  101. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine. 2005;11:1230–1237
  102. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. Journal of Immunology. 2004;172:1333–1339
  103. Zheng C, Ostad M, Andersson M, et al. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. British Journal of Haematology. 2002;118:778–785
  104. Frohn C, Hoppner M, Schlenke P, et al. Anti-myeloma activity of natural killer lymphocytes. British Journal of Haematology. 2002;119:660–664
  105. Alici E, Konstantinidis KV, Sutlu T, et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Experimental Hematology. 2007;35:1839–1846
  106. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155–3162
  107. Chatterjee M, Chakraborty T, Tassone P. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. European Journal of Cancer. 2006;42:1640–1652
  108. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517–526
  109. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 1989;74:11–13
  110. Vink A, Coulie P, Warnier G, et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. The Journal of Experimental Medicine. 1990;172:997–1000
  111. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995;86:685–691
  112. van Zaanen HC, Koopmans RP, Aarden LA, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. The Journal of Clinical Investigation. 1996;98:1441–1448
  113. van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal of Haematology. 1998;102:783–790
  114. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78:1198–1204
  115. Moreau P, Harousseau JL, Wijdenes J, et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal of Haematology. 2000;109:661–664
  116. Rossi JF, Fegueux N, Lu ZY, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation. 2005;36:771–779
  117. Stevenson FK, Bell AJ, Cusack R, et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 1991;77:1071–1079
  118. Kretz-Rommel A, Qin F, Dakappagari N, et al. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. Journal of Immunology. 2008;180:699–705
  119. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Research. 2004;64:2846–2852
  120. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research. 2005;65:5898–5906

PII: S1521-6926(08)00063-7

doi: 10.1016/j.beha.2008.07.007

Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 559-577 , September 2008

Article Tools